
A new study has found that PET/CT scanning is helpful in detecting breast tumours which have reached nearby bones.
Memorial Sloan-Kettering Cancer Centre investigators suggest that the new findings may mean less stress and more timely therapy for patients, and could make the long-time use of radionuclide bone scans for breast cancer obsolete.
Advertisement
Bone scans detect bony regions in the process of growth or repair, which can be a sign of metastatic disease. PET, on the other hand, assesses irregularities of biochemical activity in the body, such as cells that metabolise glucose unusually fast. Such behaviour is a trademark of a cancer cell. Meanwhile, CT creates anatomical images that can help physicians isolate and analyse the size and shape of tumours.
"In contrast with bone scans, which are only able to detect bone metastases, PET/CT has the advantage of concurrently imaging other common sites of breast cancer metastases such as the liver and lungs," said lead author Patrick Morris, a breast cancer specialist at Memorial Sloan-Kettering.
Morris added that the results should be interpreted with caution.
"If this data holds true in a prospective trial, the issue can be laid to rest and PET/CT could replace CT plus bone scan," noted Maxine Jochelson, Director of Radiology for the Breast and Imaging Center.
The study is published in the June 2010 issue of the Journal of Clinical Oncology.
Source: ANI
Advertisement
Morris added that the results should be interpreted with caution.
"If this data holds true in a prospective trial, the issue can be laid to rest and PET/CT could replace CT plus bone scan," noted Maxine Jochelson, Director of Radiology for the Breast and Imaging Center.
The study is published in the June 2010 issue of the Journal of Clinical Oncology.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.

The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.

A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.

Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.

Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.